Physician profile
Dhiren Kumar
NPI 1629162938
$8,403.56
in general payments reported to CMS, 2019-2025
11 companies · $8,041 in 2025
The $8,041 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.08 · 2021: $23.33 · 2022: $155 · 2023: $86.76 · 2025: $8,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,125 · Consulting Fee: $1,350 · Food and Beverage: $985 · Travel and Lodging: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,125.30 |
| Consulting Fee | $1,350.00 |
| Food and Beverage | $985.20 |
| Travel and Lodging | $667.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox Ltd | $6,081.65 | 2025 | |
| One Lambda, INC. | $1,350.00 | 2025 | |
| Apellis Pharmaceuticals, INC. | $444.67 | 2025 | Empaveli |
| Sanofi-Aventis U.S. LLC | $135.75 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $97.08 | 2019 | |
| Genzyme Corporation | $91.00 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $60.71 | 2021-2025 | Envarsus |
| Novartis Pharmaceuticals Corporation | $57.69 | 2025 | |
| Alexion Pharmaceuticals, INC. | $43.99 | 2022-2023 | Ultomiris |
| Kerecis Limited | $41.02 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhiren Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.